Forma

PeakActivity Partners with Unity Technologies to Deliver Novel Solutions to Clients

Retrieved on: 
Tuesday, August 31, 2021
Industry, CAD, Technology, Forma, Growth, Partnership, Innovation, Efficiency, Machine learning, NYSE, E-commerce, Digital marketing, 3D, Education, Virtual reality, VP, BIM, Tutoring

PeakActivity will utilize Unity's technology to create innovative solutions for its clients, specifically in the areas of machine learning, virtual reality, augmented reality, and tech applications, as well as provide Unity licenses to its clients.

Key Points: 
  • PeakActivity will utilize Unity's technology to create innovative solutions for its clients, specifically in the areas of machine learning, virtual reality, augmented reality, and tech applications, as well as provide Unity licenses to its clients.
  • PeakActivity will then provide this same training to its clients, as well as develop customized software solutions for them using the same Unity technology.
  • "Their software solutions and commitment to the future align perfectly with the core values of PeakActivity and its clients."
  • Rather than being limited to ad-hoc projects, PeakActivity clients will be able to expand their tools and co-create more customized solutions.

Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021

Retrieved on: 
Friday, August 6, 2021
Pharmaceutical, Health, Oncology, Clinical Trials, Conference, Forma, Therapy, Research, Patient, LinkedIn, Nasdaq, Degenerative disease, Cancer, Pharmaceutical industry

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release second quarter 2021 financial results Friday, Aug. 13, 2021.

Key Points: 
  • Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release second quarter 2021 financial results Friday, Aug. 13, 2021.
  • Forma management will host an investment community conference call at 8 a.m. Eastern Time, on Aug. 13, 2021, to discuss these financial results and provide a business update.
  • Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers.
  • Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.

IFF Presents “Learning Labs” Video Series to Demonstrate Potential of New Company

Retrieved on: 
Thursday, April 15, 2021
Finance, Food, Beverage, Cosmetics, Retail, Professional services, Pro forma, Invoice, Forma

In addition, the pro forma historical segment information does not purport to project the future operating results of the Company.\nDollar amounts may not foot due to rounding.\nThe first quarter and Pro Forma FY 2020 (excl.

Key Points: 
  • In addition, the pro forma historical segment information does not purport to project the future operating results of the Company.\nDollar amounts may not foot due to rounding.\nThe first quarter and Pro Forma FY 2020 (excl.
  • N&B Jan.) show the combination of the historical results of IFF and N&B as if the N&B transaction had been consummated on February 1, 2020.
  • Therefore, the first quarter and Pro Forma FY 2020 (excl.
  • Therefore, Pro Forma FY 2020 includes a full twelve months of 2020 N&B and IFF results.\nEffective 2021, we calculate currency neutral growth by translating current year invoiced sale amounts at the average exchange rates used for the corresponding prior year period.

AmpliTech's Momentum Continues with 3Q 2019 Results

Retrieved on: 
Tuesday, November 12, 2019
Electronic circuits, OTC Markets Group, Forma, Amplifier, Electronic filter, Technology

BOHEMIA, N.Y., Nov. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE AmpliTech Group, Inc. (OTCQB: AMPG)

Key Points: 
  • BOHEMIA, N.Y., Nov. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE AmpliTech Group, Inc. (OTCQB: AMPG)
    Revenue for the nine months to September 30, 2019 reaches $3.06 million on a Pro Forma basis ($2.01 million actual).
  • AmpliTech Group Inc. (AMPG), a leading high performance RF Microwave components producer, today announced financial results for its third quarter ended September 30, 2019.
  • A more detailed analysis of the Pro Forma analysis of the SMW acquisition will be contained in the Super 8-K which will be filed by November 27, 2019.
  • Brandon has over 14 years experience in our industry and specializes in low noise amplifiers and filters, two of our core areas of focus.